uniQure Past Earnings Performance
Past criteria checks 0/6
uniQure's earnings have been declining at an average annual rate of -12%, while the Biotechs industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 16.4% per year.
Key information
-12.0%
Earnings growth rate
-8.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 16.4% |
| Return on equity | -202.3% |
| Net Margin | -1,562.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 03
uniQure: The Valuation Got More Attractive
Feb 01Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding
Jan 17A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)
Dec 15Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)
Aug 27Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be
Aug 06Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money
Aug 02uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough
Jul 02Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher
Jun 28uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 14Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
Apr 11News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat
Mar 01Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
Dec 09uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion
Sep 21uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch
Aug 30uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
Aug 14uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy
Aug 08These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Jun 08uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 04uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications
Apr 08We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings
Mar 04The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically
Feb 27Is uniQure (NASDAQ:QURE) A Risky Investment?
Feb 23uniQure: Betting On Hemophilia-B Cure
Jan 18UniQure: Leading Gene Therapy Company
Nov 06These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Oct 24How We Are Playing UniQure
Oct 04Is uniQure N.V. (NASDAQ:QURE) Trading At A 48% Discount?
Sep 19Revenue & Expenses BreakdownBeta
How uniQure makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 19 | -297 | 71 | -20 |
| 31 Dec 23 | 16 | -308 | 75 | 0 |
| 30 Sep 23 | 112 | -228 | 75 | 0 |
| 30 Jun 23 | 112 | -187 | 71 | 0 |
| 31 Mar 23 | 110 | -157 | 62 | 0 |
| 31 Dec 22 | 106 | -127 | 55 | 0 |
| 30 Sep 22 | 61 | -125 | 51 | 0 |
| 30 Jun 22 | 62 | -114 | 49 | 0 |
| 31 Mar 22 | 525 | 324 | 55 | 0 |
| 31 Dec 21 | 524 | 330 | 56 | 0 |
| 30 Sep 21 | 500 | 321 | 54 | 0 |
| 30 Jun 21 | 500 | 303 | 52 | 0 |
| 31 Mar 21 | 38 | -139 | 46 | 0 |
| 31 Dec 20 | 38 | -125 | 43 | 0 |
| 30 Sep 20 | 6 | -166 | 40 | 0 |
| 30 Jun 20 | 5 | -136 | 38 | 0 |
| 31 Mar 20 | 6 | -124 | 35 | 0 |
| 31 Dec 19 | 7 | -124 | 34 | 0 |
| 30 Sep 19 | 6 | -105 | 32 | 0 |
| 30 Jun 19 | 8 | -103 | 29 | 0 |
| 31 Mar 19 | 9 | -92 | 27 | 0 |
| 31 Dec 18 | 11 | -83 | 25 | 0 |
| 30 Sep 18 | 12 | -90 | 26 | 0 |
| 30 Jun 18 | 11 | -78 | 25 | 0 |
| 31 Mar 18 | 13 | -78 | 25 | 0 |
| 31 Dec 17 | 13 | -79 | 25 | 0 |
| 30 Sep 17 | 20 | -67 | 24 | 0 |
| 30 Jun 17 | 25 | -72 | 23 | 0 |
| 31 Mar 17 | 24 | -71 | 26 | 0 |
| 31 Dec 16 | 25 | -73 | 25 | 0 |
| 30 Sep 16 | 20 | -76 | 28 | 0 |
| 30 Jun 16 | 16 | -90 | 29 | 0 |
| 31 Mar 16 | 14 | -90 | 26 | 0 |
| 31 Dec 15 | 11 | -82 | 23 | 0 |
| 30 Sep 15 | 8 | -76 | 18 | 0 |
| 30 Jun 15 | 6 | -58 | 16 | 0 |
| 31 Mar 15 | 5 | -45 | 14 | 0 |
| 31 Dec 14 | 6 | -50 | 17 | 0 |
| 30 Sep 14 | 5 | -41 | 15 | 0 |
| 30 Jun 14 | 6 | -42 | 17 | 0 |
| 31 Mar 14 | 6 | -41 | 17 | 0 |
| 31 Dec 13 | 4 | -37 | 16 | 0 |
| 30 Sep 13 | 3 | -33 | 10 | -7 |
| 30 Jun 13 | 1 | -27 | 8 | -5 |
Quality Earnings: QURE is currently unprofitable.
Growing Profit Margin: QURE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: QURE is unprofitable, and losses have increased over the past 5 years at a rate of 12% per year.
Accelerating Growth: Unable to compare QURE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: QURE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: QURE has a negative Return on Equity (-202.29%), as it is currently unprofitable.